Patients with relapsed stage 4 neuroblastoma have an extremely poor long-term prognosis, making the investigation of new agents of interest. We report the outcome of the first patient treated in a phase 1 study for relapsed neuroblastoma, using the chemotherapy agent decitabine to upregulate cancer testis antigen expression, followed by a dendritic cell vaccine targeting the cancer testis antigens MAGE-A1, MAGE-A3, and NY-ESO-1. Our patient had persistent tumor in his bone marrow after completion of standard therapy for neuroblastoma, including multiagent chemotherapy, tumor resection, stem cell transplantation, radiation therapy, and anti-GD2 monoclonal antibodies. His marrow disease persisted despite chemotherapy, which was given while the vaccine was being produced. After 3 cycles of decitabine and vaccine, this patient achieved a complete remission and is now 1 year from his last treatment, with no evidence of tumor in his bone marrow or other sites. This patient was noted to have an increase in MAGE-A3–specific T cells. This is the first report combining demethylating chemotherapy to enhance tumor antigen expression followed by a cancer antigen vaccine. *Pediatrics* 2013;131:e336–e341
Neuroblastoma is the most common extracranial solid tumor in children, and for those older than 1 year with advanced disease, the 3-year progression-free survival rate is only 40%, despite the current use of multiagent chemotherapy, radiation, and autologous stem cell transplantation.\textsuperscript{1,2} Yu et al reported that the addition of anti-GD2 monoclonal antibody therapy to this standard regimen improved 2-year event-free survival from 46% to 66%.\textsuperscript{3} Unfortunately, half of patients with stage 4 neuroblastoma will eventually have a relapse, and there are currently no options with curative potential when this occurs. Immunotherapy is complicated by the fact that there is varying expression of tumor antigens on this tumor as well as the downregulation of major histocompatibility complex (MHC) class I and II molecules, which are needed for antigen presentation.\textsuperscript{4,5} We have developed a clinical study that combines the administration of a chemotherapy agent to upregulate cancer antigen expression, followed by a vaccine targeting these antigens. Cancer testis (CT) antigens such as NY-ESO-1, MAGE-A1, and MAGE-A3 have a restricted pattern of expression, generally limited to germ cell and trophoblast tissue, but also expressed on a variety of solid tumors, including neuroblastoma.\textsuperscript{6–8} Decitabine (5-aza-2’-deoxycytidine [DAC]), a potent inhibitor of DNA methylation,\textsuperscript{9–12} has been shown to upregulate the expression of CT antigens in a number of tumor cell lines,\textsuperscript{13,14} potentially making these tumors more susceptible to MAGE-A1–, MAGE-A3–, and NY-ESO-1–mediated killing. At our laboratory, we have recently demonstrated that MAGE-A1, MAGE-A3, and NY-ESO-1 expression is upregulated after exposure to DAC in most neuroblastoma cell lines, including tumors that lacked expression pretreatment.\textsuperscript{15}

Multiple clinical trials have reported using MAGE-A1, MAGE-A3, and NY-ESO-1 vaccines for adult solid tumors, with clinical and immunologic responses detected postvaccination.\textsuperscript{16–19} There have been no clinical studies targeting these antigens for neuroblastoma. We initiated a phase I CT antigen vaccine trial for patients with relapsed neuroblastoma, first upregulating CT antigen expression by administering DAC, followed by an autologous dendritic cell (DC) — MAGE-A1, MAGE-A3, NY-ESO-1 vaccine. This report describes the outcome of the first patient treated on this trial.

**PATIENT PRESENTATION**

Our patient is a 6-year-old boy who presented to the hospital at 3 years of age with bone pain and a large posterior mediastinal mass extending from the carina to the lumbar spine, with a 10×12–cm left suprarenal mass. There were clumps of tumor cells on bilateral bone marrow aspirates and multiple bony metastases shown on bone scan. Urine catecholamine measure and meta-iodo-benzyl-guanidine scan were negative. A biopsy of his abdominal mass revealed an undifferentiated, unfavorable-histology neuroblastoma (schwannian stroma–poor tumor) that was n-myc–nonamplified and of mitosis-karyorrhexis index of 2% to 4%. The patient was approved for treatment in Children’s Oncology Group (COG) study ANBL0532; after the initial 2 cycles of chemotherapy, he had a very good response at his primary tumor site and had negative bone marrow aspirates. He was treated with 3 additional cycles of induction chemotherapy and underwent surgical resection of his abdominal tumor, at which time pathologic examination of his tumor was consistent with mature ganglioneuroblastoma. Bilateral bone marrow aspirates and biopsies were negative before stem cell transplantation, and bone examination revealed resolution of the majority of his bony lesions, with persistent metastatic disease within T12 and the sacroiliac joints. He was randomized to receive a single transplant with carboplatin, etoposide, and melphalan and radiation therapy and then underwent treatment in COG ANBL0032 for immunotherapy with anti-GD2 monoclonal antibody ch14.18, interleukin (IL)-2, 13-cis-retinoic acid, and granulocyte-macrophage colony-stimulating factor. His end-of-therapy evaluation showed tumor clumps on bilateral bone marrow aspirates and, despite 3 cycles of irinotecan and temozolomide, his marrow disease...
Peripheral blood mononuclear cells were collected via apheresis for the culture of dendritic cells and the patient began therapy with the DAC/DC vaccine regimen. This study has been approved by the Penn State Hershey Medical Center Institutional Review Board and the US Food and Drug Administration (IND 13973).

Our patient received 3 monthly cycles of DAC 10 mg/m²/d for 5 days, with each cycle followed by 2 weekly vaccines consisting of autologous DC pulsed with overlapping peptides derived from full-length MAGE-A1, MAGE-A3, and NY-ESO-1 (JPT Peptide Technologies, Berlin, Germany). The Toll-like receptor agonist imiquimod was used at the vaccine site before and after vaccination, to facilitate immune cell infiltration into the vaccine site. After 3 cycles, the patient had no evidence of tumor on bilateral bone marrow aspirates and biopsy samples. During the third treatment cycle, a transient increase in alkaline phosphatase was observed from weeks 3 to 5 (range 1428–5185 IU/L), which fell to 685 IU/L (normal range 80–420 IU/L) by week 8 after receiving DAC. This was initially thought to represent DAC-induced hepatotoxicity, but serum transaminase and bilirubin levels were normal during this time, and fractionation of the alkaline phosphatase confirmed that it was 70% bone and 30% liver isozyme. C-telopeptide, a sensitive marker of bone reabsorption, was elevated at 2516 pg/mL (range 574–1849 pg/mL). Pretreatment C-telopeptide levels are not available for comparison. This increase in alkaline phosphatase correlated with a decline in the patient’s neutrophil and platelet count, which resolved 3 weeks later. There was no evidence of tumor on bilateral bone marrow aspirates and

**FIGURE 2**

Detection of antigen-specific T cells in patient 1 at different time points (before and after vaccination). The patient received 3 cycles of therapy. Each cycle consists of 1 week of DAC (DAC-1: Cycle 1, one week of DAC; DAC-2: Cycle 2, one week of DAC; and DAC-3: Cycle 3, one week of DAC) followed by vaccine 1 (v-1), vaccine 2 (v-2), and a week of rest as indicated in the bottom panel. The numbers of CD3⁺CD8⁺CD137⁺ and CD3⁺CD4⁺CD137⁺ antigen-specific cells per 10⁶ cells in the peripheral blood at intervals postvaccination are represented. T cells were assayed 24 hours poststimulation with MAGE-A1 (MA1), MAGE-A3 (MA3), or NY-ESO-1 (NY) overlapping peptide mixes (JPT Peptide Technologies).
biopsy samples 4 weeks after the start of cycle 3. One year after his last vaccination, the patient’s bone marrow remains morphologically free of tumor, including by immunohistochemistry for NB84 (Genzyme Genetics, Los Angeles, CA), and computed tomography scans of the chest, abdomen, and pelvis are normal.

Analysis of T cells postvaccination revealed that the number of MAGE-A3–specific, CD3+CD8+CD137+ T cells increased from 25 cells/10^6 to 175 cells/10^6 at 1 month postvaccination, and these levels declined to 60 cells/10^6 for the ensuing 2 months (Fig 2). MAGE-A3–specific, CD8+ T cells were at pre-treatment baseline levels (range 25–50 cells/10^6) at 3, 6, and 9 months after the last vaccination. A similar trend was seen for CD3+CD4+CD137+ T cells responding to MAGE-A3. The percentages of both CD8 and CD4 effector memory T cells (CD3+CD8+/CD4+CD137CCR7CD45RA−) increased after the first vaccination (Fig 3), but it is unclear why the most striking increase was seen at this time point and not after subsequent vaccines, and antigen-specific CD4+ effector memory T cells increased at 6 and 9 months.

**DISCUSSION**

The prognosis for patients with relapsed neuroblastoma is extremely poor, considering that these tumors recur after high-dose chemotherapy and radiation. Additional use of multi-agent chemotherapy or radiotherapy generally results in only temporary control of disease, so novel approaches are needed for these patients. Neuroblastomas have several potential escape mechanisms from immune surveillance, including the down-regulation of MHC molecules and potentially immunogenic cancer antigens.4,5,20

To facilitate immune recognition and killing of tumor cells by cytotoxic T lymphocytes (CTLs) that would be expanded after a CT antigen vaccine, we administered low-dose DAC before immunotherapy. Previous studies have shown that MAGE antigen–specific CTLs preferentially kill tumor cells that have had CT antigens upregulated after exposure to DAC, but this has not been tested in a clinical trial.15,21 Several studies have been done with MAGE-A1, MAGE-A3, and NY-ESO-1 vaccines for
adult cancers using either single MHC-restricted epitopes or whole protein, with clinical and immunologic responses seen in some patients.\textsuperscript{16–18} We decided to use a mixture of peptides derived from each full-length antigen, so that patients could be enrolled from diverse HLA backgrounds. With our preclinical data on CT antigen upregulation on tumors and well-documented safety of CT antigen vaccines in adults, we initiated the current trial, considering the poor long-term prognosis for these patients and theoretical potential for efficacy.

Immunotherapy studies for neuroblastoma have largely focused on the anticancer effects of monoclonal antibodies directed against GD2, which is expressed on the majority of these tumors.\textsuperscript{22,23} Recently, Louis et al\textsuperscript{24} reported the use of anti-GD2 chimeric antigen receptor expressing CTLs in patients with neuroblastoma and found that 3 of 11 patients with active disease achieved a complete remission. Caruso et al\textsuperscript{25} reported the use of an autologous DC–tumor RNA vaccine in 11 children with newly diagnosed neuroblastoma, after the completion of standard therapy, and none of the patients with measurable disease showed an objective antitumor response. Russell and colleagues gave patients with neuroblastoma a vaccine consisting of autologous tumor cells that were transduced to express IL-2 or IL-2 and lymphotactin.\textsuperscript{26,27} While there were detectable interferon-\textgamma--producing, autologous tumor–specific T cells in the peripheral blood of some patients postvaccination, the median event-free survival was only 3 months for patients with relapsed disease. These studies show that clinical and immunologic responses are possible with various immunotherapy regimens for neuroblastoma, but new strategies are desperately needed.

Our patient developed an antigen-specific T-cell response postvaccination, most notably against MAGE-A3. It is unclear whether this response was due to chemotherapy, an immune response to the vaccine, or both. Of note is the fact that he developed transient leukopenia and thrombocytopenia at the same time his alkaline phosphatase level became markedly elevated, suggesting that an immune response targeting hematopoietic precursors had been induced. Nevertheless, our patient’s clinical response could have been solely the result of the DAC. In addition to facilitating expression of CT antigens on tumor cells, DAC also upregulates the proapoptotic gene caspase-8, restoring its expression and making neuroblastoma cells more susceptible to apoptosis.\textsuperscript{28} A phase 1 study for children with relapsed neuroblastoma and other solid tumors used DAC with doxorubicin and cyclophosphamide, with little efficacy.\textsuperscript{29} There are little data on this drug used alone in patients with isolated marrow disease, although one of the patients for whom the regimen failed as reported by George et al (personal communication) had disease isolated to the bone marrow.

The effects of DAC in facilitating the expression of CT antigens and MHC molecules before vaccination could overcome immune evasion strategies and serve to enhance CT antigen–specific immune responses in patients with neuroblastoma as well as other tumors. Although these results are encouraging, this reports depicts the outcome of a single patient with chemotherapy-resistant, microscopic disease in the marrow. It remains to be seen whether this regimen will result in clinical responses in patients with bulky tumors. Additional research is also needed to determine how DAC-treated tumor cells are being killed and whether there are concomitant humoral responses after this vaccine regimen.

REFERENCES

11. Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating...


Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma

Deepa Kolaseri Krishnadas, Teresa Shapiro and Kenneth Lucas

*Pediatrics* 2013;131;e336

DOI: 10.1542/peds.2012-0376 originally published online December 24, 2012;

Updated Information & Services

including high resolution figures, can be found at:

http://pediatrics.aappublications.org/content/131/1/e336

References

This article cites 29 articles, 10 of which you can access for free at:

http://pediatrics.aappublications.org/content/131/1/e336.full#ref-list-1

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

**Genetics**

http://classic.pediatrics.aappublications.org/cgi/collection/genetics_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

https://shop.aap.org/licensing-permissions/

Reprints

Information about ordering reprints can be found online:

http://classic.pediatrics.aappublications.org/content/reprints
ERRATA


An error occurred in this article by Krishnadas et al, titled “Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma,” published in the January 2013 issue of Pediatrics (2013;131[1]:e336–e341; doi:10.1542/peds.2012-0376). On page e336, under the Funding section, the copy reads: “This work was supported by funds from the Four Diamonds Fund, Hyundai Hope on Wheels and Solving Kids’ Cancer.” This should have read: “This work was supported by funds from the Four Diamonds Fund, Hyundai Hope on Wheels, Solving Kids’ Cancer, The Andrew McDonough B+ Foundation, and the Pierce Phillips Charity.”

doi:10.1542/peds.2013-1141
Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma

Deepa Kolaseri Krishnadas, Teresa Shapiro and Kenneth Lucas

Pediatrics 2013;131:e336

DOI: 10.1542/peds.2012-0376 originally published online December 24, 2012;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/131/1/e336

An erratum has been published regarding this article. Please see the attached page for: